{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["100(11)"],"submitter":["Reinert J"],"funding":["Universitätsklinikum Hamburg-Eppendorf (UKE)"],"pubmed_abstract":["Treatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody-drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. Flow cytometry is essential to assess antigen-expression prior to treatment initiation of antigen-directed immunotherapies. Here, we present flow cytometric and clinical data of three adult patients with r/r B-ALL who failed treatment with InO associated with reduced or lost antigen-expression. In addition, we present comparative data on two different diagnostic CD22-specific antibody clones that exhibit significant differences in staining intensities."],"journal":["Annals of hematology"],"pagination":["2727-2732"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8510963"],"repository":["biostudies-literature"],"pubmed_title":["Loss of CD22 expression and expansion of a CD22<sup>dim</sup> subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin."],"pmcid":["PMC8510963"],"pubmed_authors":["Schwartz S","Reinert J","Beitzen-Heineke A","Fiedler W","Wethmar K","Stelljes M"],"additional_accession":[]},"is_claimable":false,"name":"Loss of CD22 expression and expansion of a CD22<sup>dim</sup> subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.","description":"Treatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody-drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. Flow cytometry is essential to assess antigen-expression prior to treatment initiation of antigen-directed immunotherapies. Here, we present flow cytometric and clinical data of three adult patients with r/r B-ALL who failed treatment with InO associated with reduced or lost antigen-expression. In addition, we present comparative data on two different diagnostic CD22-specific antibody clones that exhibit significant differences in staining intensities.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-04T12:22:49.735Z","creation":"2025-02-19T01:26:16.169Z"},"accession":"S-EPMC8510963","cross_references":{"pubmed":["34331563"],"doi":["10.1007/s00277-021-04601-0"]}}